|
Status |
Public on Mar 10, 2016 |
Title |
Tumor28 |
Sample type |
genomic |
|
|
Channel 1 |
Source name |
glioblastoma tissue
|
Organism |
Homo sapiens |
Characteristics |
clinical_subgroup: short-term survivor (STS) tissue type: glioblastoma
|
Growth protocol |
Not applicable
|
Extracted molecule |
genomic DNA |
Extraction protocol |
Tumor tissue was snap-frozen and stored at -80°C until further processing. DNA was extracted with the QIAmp DNA Mini Kit (Qiagen) from samples found eligible in terms of tumor cell content (>60%) and necrosis (<20%). Analyte concentration and quality were determined using the Nanodrop 2000 spectrophotometer (Thermo Scientific) and Bioanalyzer 2100 (Agilent). For enrichment of hypermethylated DNA fractions, Methyl-CpG-binding domain (MBD)-Fc protein was produced and MCIp performed as previously described (Schilling et al., Genomics 2007). Briefly, 75 µg of MBD-Fc protein was coupled to 50 µl SIMAG protein A magnetic beads (Chemicell) at 4°C overnight. After binding of 2 µg sonicated DNA, the DNA was eluted with increasing NaCl concentrations (300-1000 mM) using the MagnetoPure-Micro bead separator (Chemicell). Lowly and highly methylated DNA was eluted at the lowest and highest concentrations, respectively. DNA enrichment was monitored by real-time PCR targeting known unmethylated and methylated DNA regions.
|
Label |
Cy5
|
Label protocol |
Highly methylated glioblastoma and normal brain control DNA were labeled with Alexa Fluor 5 and Alexa Fluor 3, respectively.
|
|
|
Channel 2 |
Source name |
normal brain tissue
|
Organism |
Homo sapiens |
Characteristics |
tissue type: normal brain
|
Growth protocol |
Not applicable
|
Extracted molecule |
genomic DNA |
Extraction protocol |
Tumor tissue was snap-frozen and stored at -80°C until further processing. DNA was extracted with the QIAmp DNA Mini Kit (Qiagen) from samples found eligible in terms of tumor cell content (>60%) and necrosis (<20%). Analyte concentration and quality were determined using the Nanodrop 2000 spectrophotometer (Thermo Scientific) and Bioanalyzer 2100 (Agilent). For enrichment of hypermethylated DNA fractions, Methyl-CpG-binding domain (MBD)-Fc protein was produced and MCIp performed as previously described (Schilling et al., Genomics 2007). Briefly, 75 µg of MBD-Fc protein was coupled to 50 µl SIMAG protein A magnetic beads (Chemicell) at 4°C overnight. After binding of 2 µg sonicated DNA, the DNA was eluted with increasing NaCl concentrations (300-1000 mM) using the MagnetoPure-Micro bead separator (Chemicell). Lowly and highly methylated DNA was eluted at the lowest and highest concentrations, respectively. DNA enrichment was monitored by real-time PCR targeting known unmethylated and methylated DNA regions.
|
Label |
Cy3
|
Label protocol |
Highly methylated glioblastoma and normal brain control DNA were labeled with Alexa Fluor 5 and Alexa Fluor 3, respectively.
|
|
|
|
Hybridization protocol |
Oligoarray control targets and hybridization buffer (Agilent In Situ Hybridization Kit Plus) were added, and samples were applied to microarrays enclosed in Agilent SureHyb-enabled hybridization chambers. After hybridization, slides were washed sequential
|
Scan protocol |
Scanned on an Agilent G2505B scanner. Images were quantified using Agilent Feature Extraction Software.
|
Description |
DNA was enriched for hypermethylated fractions by Methyl-CpG Immunoprecipitation (MCIp)
|
Data processing |
Scanning raw data were processed using the statistical environment R. Background correction and log2 transformation were performed according to the NormExp method with offset = 50 (Ritchie et al., Bioinformatics 2007). Intensity-based LOESS normalization was applied to rank-invariant probes and negative controls in order to reduce technical noise between samples (Tseng et al., Nucleic Acids Res 2001). For intra-array normalization, log-intensity ratios (M-value) and log-intensity averages (A-values) were scaled to have the same median-absolute value across the array.
|
|
|
Submission date |
Nov 02, 2015 |
Last update date |
Mar 10, 2016 |
Contact name |
Christel Herold-Mende |
Organization name |
Heidelberg University Hospital
|
Department |
Department of Neurosurgery
|
Lab |
Experimental Neurosurgery
|
Street address |
Im Neuenheimer Feld 400
|
City |
Heidelberg |
ZIP/Postal code |
69117 |
Country |
Germany |
|
|
Platform ID |
GPL9767 |
Series (1) |
GSE74561 |
LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients |
|